Methods of treating tumors with anti-TIGIT antibodies

The present disclosure relates to methods of treating or the manufacture of a medicament for treating cancer by using pharmaceutical formulations or medicaments comprising anti-TIGIT monoclonal antibodies that are suitable for co-administration or co-formulation with anti-PD-L1 monoclonal antibodies...

Full description

Saved in:
Bibliographic Details
Main Authors TSCHUDI, KATHERINE LAURA, SUHLING, ROBYN MARIAH, WOYS, ANN MARIE, SANE, RUCHA SUDHAKAR, SHIEH, IAN CHUNG-TI, CHAN, HUI MIN PHYLLIS, ROONEY, ISABELLE ANNE, WEN, XIAOHUI
Format Patent
LanguageChinese
English
Published 16.12.2024
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The present disclosure relates to methods of treating or the manufacture of a medicament for treating cancer by using pharmaceutical formulations or medicaments comprising anti-TIGIT monoclonal antibodies that are suitable for co-administration or co-formulation with anti-PD-L1 monoclonal antibodies. The present disclosure also relates to articles of manufacture comprising single doses of anti-TIGIT monoclonal antibodies or both anti-TIGIT and anti-PD-L1 monoclonal antibodies and methods of treating cancer using such articles of manufacture and the formulations contained therein.
Bibliography:Application Number: TW20240112381